New National Health Sciences Accelerator, Accel-Rx Formally Launched as a Centre of Excellence for Commercialization and Research

Date Posted: 
2014-08-25

With the awarding of $14.5M under the Canadian government’s Networks of Centres of Excellence (Centres of Excellence for Commercialization and Research (CECR)) Program, as announced earlier this morning by the Honourable Ed Holder, Minister of State for Science and Technology, Accel-Rx - Canada’s Health Sciences Accelerator is officially launched.

The Accel-Rx Health Sciences Accelerator is a national organization focused on maximizing new health sciences company creation, and ensuring start-ups have the resources they need to enable them to stay and grow in Canada and give rise to a new generation of strong health sciences anchor companies. Accel-Rx therein brings together five of Canada’s leading health sciences CECRs to foster pan-Canadian cooperation and directly address the health science company creation challenge in Canada. These CECRs include:

CDRD Ventures Inc. (CVI), the commercialization vehicle of The Centre for Drug Research and Development will provide the initial management to launch Accel-Rx’s operations. BDC Venture Capital, as recently announced, will further advance Accel-Rx’s mission by acting as the main funding mechanism for companies created at and/or supported by Accel-Rx, with the intent to invest in up to three to four companies annually, with that number potentially increasing as the partnership progresses. Selected companies would each receive a $500,000 convertible note from BDC Venture Capital (allowing companies to attract similar, if not greater investments from the private sector).

Read the full announcement here (PDF opens in new window)

Specific resources provided by Accel-Rx to support new company creation include:

  • Seed capital through its partnership with BDC Venture Capital;
  • Access to a new national network of entrepreneurs to drive and guide company creation;
  • Partnerships with the venture capital community to facilitate follow-on financings as well as provide early
  • business feedback;
  • Access to and commercial input from strategic industry partners;
  • Business/finance/development expertise, technical capabilities and specialized infrastructure;
  • Specialized entrepreneurial training to enable young, driven individuals to become the next generation of
  • company creators and bio-entrepreneurs;
  • Regular meetings and events to bring together these investors, entrepreneurs, researchers, industry partners,
  • and technology developers.

By bringing these resources to bear, Accel-Rx, will provide Canada with a new more well-informed, well-resourced, and effective approach to company creation; and ensure that opportunities arising from the country’s strong foundation of innovative discovery research and technology development are fully capitalized upon through the launching of a critical mass of robust companies based on exceptional innovative, pre-validated (scientifically and commercially) technologies.

For additional information, please contact:
Barry Gee
Director, Communications
CDRD/CVI
Direct: 604-827-1223604-827-1223 
bgeeatcdrd [dot] ca

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

PCF BC

Ride to Live 2018 and 50-50 Draw: May 27

The West Coast Motorcycle Ride to Live, raising funds for Prostate Cancer Foundation BC, takes place on Sunday May 27, 2018 in Vancouver, Victoria & the Fraser Valley. Follow the links to join a ride or donate to a rider; or to buy a ticket for a 50/50 draw (BC residents only).

Employment

Work at the Vancouver Prostate Centre

Thursday, January 18, 2018

Discovery of a promising new medication to block "master key" of cancer growth

Dr. Chris Ong
Tuesday, February 20, 2018

Drs. Wyatt and Chi: ctDNA predicts resistance to AR-targeted therapy

VCHRI News article on study of ctDNA predicting resistance to AR-targeted therapy
DNA

Make A Difference

Help the Vancouver Prostate Centre fund research to find better treatments and a cure.